RPS6 and B-cell non-Hodgkin lymphoma: In mantle cell lymphoma (MCL), a clinically aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) and overexpression of cyclin D1, stimulation of the AMPK kinase activity using AICAR inhibited phosphorylation of critical downstream effectors of mTOR signaling, such as 4E-BP1 and ribosomal protein s6 (rps6) (57).